Filing Flows › Amneal Pharmaceuticals (AMRX) › Gross margin
Amneal Pharmaceuticals (AMRX) gross margin by quarter
Amneal Pharmaceuticals' gross margin was 38.7% in Q3 2026 (third quarter 2026), -3.3 pts from Q2 2026. Over the last 6 quarters it ranged from 36.5% (Q4 2025) to 44.3% (Q1 2026).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 38.7% | -3.3 pts | — |
| Q2 2026 | 42.0% | -2.3 pts | +2.5 pts |
| Q1 2026 | 44.3% | +7.8 pts | +7.5 pts |
| Q4 2025 | 36.5% | -3.0 pts | — |
| Q2 2025 | 39.5% | +2.7 pts | — |
| Q1 2025 | 36.8% | — | — |
Q3 2026 at a glance
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Amneal Pharmaceuticals' gross margin?
Amneal Pharmaceuticals' gross margin was 38.7% in Q3 2026 (third quarter 2026), -3.3 pts from Q2 2026.
How has Amneal Pharmaceuticals' gross margin changed?
Over the last 6 quarters it ranged from 36.5% (Q4 2025) to 44.3% (Q1 2026).
Q3 2026 results → · How Amneal Pharmaceuticals makes money →